Nippon India Mutual FundNippon India Pharma Fund - Direct Plan Growth Plan - Growth Option
Equity Scheme - Sectoral/ ThematicDirect planGrowthInception —
NAV vs Benchmark
Trailing Returns
| Series | 1Y | 3Y | 5Y | 10Y | SI |
|---|---|---|---|---|---|
| Scheme | 5.59% | 23.31% | 13.35% | 16.30% | 17.42% |
| Benchmark | -0.51% | 13.25% | 12.00% | 6.55% | 88.66% |
| Excess | 6.10% | 10.06% | 1.35% | 9.75% | -71.24% |
Trailing returns are annualized (CAGR) for 3Y / 5Y / 10Y and absolute for 1Y. SI is total return since the first available NAV. Benchmark returns are derived from the scheme's mandated TRI index.
Expense Ratio (TER)
Direct
—
Regular
—
Direct plans have a lower expense ratio because no distributor commission is paid. Regular plans are sold through intermediaries who provide advice.
YieldIQ Fund Score
B
77/ 100
Rule-based composite of returns, risk, cost, and tenure.
Fee impact calculator
What the expense ratio costs over time, and the Direct-vs-Regular plan gap. This scheme's expense ratios aren't on file yet; enter them from the factsheet (typical Direct ~0.5%, Regular ~1.5%).
No fees
₹3,10,585
Direct plan
₹2,96,995
Regular plan
₹2,71,408
Fee drag · Direct, 10y
₹13,590
Direct keeps more than Regular
₹25,587
Illustrative only — assumes a constant 12% gross return and the expense ratios above held flat; actual returns and fees vary. Direct plans carry no distributor commission. Not advice.